US infection control authorities recommend resuming use of the Janssen vaccine

Johnson & Johnson COVID-19 vaccine - JanssenPhoto: AP Photo / David Zalubowski
Advertisements

A panel of experts at the American Centers for Disease Control and Prevention (CDC) recommends resuming the use of the Janssen corona vaccine.

Use of the vaccine was put on hold on April 13 after several cases of blood clot symptoms in vaccinated people.

The symptoms of a blood clot and a low level of platelets were similar to those seen in relation to the use of AstraZeneca’s corona vaccine.

Of the 8 million Janssen vaccines administered in the United States so far, 15 cases of blood clots have been reported, three of which were fatal. 13 of the cases were reported in women under 50. No men are affected.

Ten of the experts on the panel voted in favor of the recommendation, while four voted against it.

The majority believe that the benefits far outweigh the small risk, as tens of thousands of Americans are infected with the coronavirus every day. US authorities will quickly consider the recommendation and make a decision shortly.

Warning to be included

According to CNN, the CDC has decided that a warning should be included alongside the vaccine so that women under 50 are made aware of the risk of rare blood clots.

Johnson & Johnson announced on Friday that they are restarting the roll-out of the Janssen vaccine in Europe after the EU Medicines Agency (EMA) requested that the risk of side effects be listed in the package insert, which Johnson & Johnson accepted.

The vaccine has not been used in Norway yet, although doses have been received. A temporary pause in the use of both the Janssen and the AstraZeneca vaccines is currently in place in Norway.

Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews

Do you have a news tip for Norway Today? We want to hear it. Get in touch at info@norwaytoday.no

Advertisements

Be the first to comment on "US infection control authorities recommend resuming use of the Janssen vaccine"

Leave a comment

Your email address will not be published.


*